Development and use of nanoFACS for analysis and sorting of nanoparticles

NanoFACS 的开发和使用用于纳米粒子的分析和分类

• 批准号: 8938164
• 负责人: Jennifer Jones
• 金额: $ 42.22万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938164
• 关键词: Biological Markers; Biology; Blood; CCR; Cells; Cooperative Research and Development Agreement; Detection; Development; Goals; Immune response; Immunobiology; Immunotherapy; Methods; Modification; Monitor; Research; Sorting - Cell Movement; Techniques; Technology; Testing; Tumor Biology; United States National Institutes of Health; Vaccines; cancer therapy; improved; instrument; nanoparticle; novel; particle

We successfully brought nanoFACS, a method for analyzing and sorting naonoscale particles, to NIH, by modifying the Influx flow cytometer in a NCI/CCR core FACS facility in Building 10. This now allows us to analyze and sort exosomes and microparticles as small as approximately 100nm. We have developed and tested numerous modifications of the technique and instrument configuration to improve the detection limits to routinely analyze and sort particles as small as 40nm (which would span the full range of biologically significant exosome sizes). We also have obtained a new instrument, a Beckman Coutler MoFlo AstriosEQ,with modifications to further improve our analystical and sorting capabilities, as part of a CRADA established between our group and Beckman. Over the next year, we will continue 1) to use this technology to identify novel biomarkers that we can use to guide and monitor the effects of cancer therapies and immune responses (to vaccines or other immunotherapies), and 2) to identify subsets of these nanoparticles and determine their functions in tumor biology, immunobiology, and other aspects of biology.

通过修改 10 号楼 NCI/CCR 核心 FACS 设施中的 Influx 流式细胞仪，我们成功地将 nanoFACS（一种用于分析和分选纳米级颗粒的方法）引入 NIH。现在，我们能够分析和分选小至约 100 nm 的外泌体和微粒。我们开发并测试了对技术和仪器配置的大量修改，以提高检测限，以常规分析和分选小至 40 nm 的颗粒（这将涵盖具有生物学意义的外泌体尺寸的全部范围）。我们还获得了一台新仪器 Beckman Coutler MoFlo AstriosEQ，经过修改以进一步提高我们的分析和分类能力，作为我们团队与 Beckman 之间建立的 CRADA 的一部分。在接下来的一年中，我们将继续 1) 使用这项技术来识别新的生物标志物，我们可以用它们来指导和监测癌症治疗和免疫反应（对疫苗或其他免疫疗法）的效果，2) 识别这些纳米粒子的子集并确定它们在肿瘤生物学、免疫生物学和生物学其他方面的功能。